These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31084771)

  • 1. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.
    Kostakoglu L; Nowakowski GS
    PET Clin; 2019 Jul; 14(3):307-315. PubMed ID: 31084771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver Agreement of Interim and End-of-Treatment
    Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
    J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
    Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
    Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
    Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
    Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
    Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
    Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
    Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
    Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
    Paksi M; Demeter J; Szabó P
    Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
    Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
    Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
    PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus
    Gómez León N; Vega G; Rodríguez-Vigil Junco B; Suevos Ballesteros C
    Med Clin (Barc); 2018 Oct; 151(7):255-264. PubMed ID: 29705152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.
    Eertink JJ; Arens AIJ; Huijbregts JE; Celik F; de Keizer B; Stroobants S; de Jong D; Wiegers SE; Zwezerijnen GJC; Burggraaff CN; Boellaard R; de Vet HCW; Hoekstra OS; Lugtenburg PJ; Chamuleau MED; Zijlstra JM;
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):943-952. PubMed ID: 34476551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT and
    Altinmakas E; Üçışık-Keser FE; Medeiros LJ; Ng CS
    Acad Radiol; 2019 Jun; 26(6):e108-e114. PubMed ID: 30076085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.